Ghrelin, another factor affecting bone metabolism

Medical Science Monitor

Volumn 16, Issue 7, 2010, Pages 147-162

  Nikolopoulos, Dimitrios ^a   Theocharis, Stamatios ^b   Kouraklis, Gregory ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Bone and cartilage metabolism; Chondrocytes; Ghrelin; Growth hormone secretagogue receptor; Osteoblasts

Indexed keywords

BUDESONIDE; CALCITONIN; CONNECTIVE TISSUE GROWTH FACTOR; CORTICOSTEROID; ESTROGEN; GHRELIN; GROWTH HORMONE; HEXARELIN; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; IBUTAMOREN; IPAMORELIN; LUTEINIZING HORMONE; PARATHYROID HORMONE; PRALMORELIN; PREDNISONE; SOMATOMEDIN B; SOMATOMEDIN C; TESTOSTERONE; THYROID HORMONE; VITAMIN D; GHRELIN RECEPTOR;

ARTHRITIS; ASH; BLOOD PRESSURE; BODY WEIGHT; BONE ATROPHY; BONE DENSITY; BONE DEVELOPMENT; BONE GROWTH; BONE METABOLISM; BONE REMODELING; CARDIOVASCULAR SYSTEM; CARTILAGE CELL; CELL MATURATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CROHN DISEASE; FRACTURE HEALING; GASTROINTESTINAL TRACT; GROWTH HORMONE RELEASE; HEART INDEX; HEART MUSCLE CELL; HEART PROTECTION; HEART STROKE VOLUME; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNE SYSTEM; LEYDIG CELL; LUTEINIZING HORMONE RELEASE; METABOLIC REGULATION; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; OSTEOLYSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; REPRODUCTION; REVIEW; SIDE EFFECT; SPERMATOGENESIS; STOMACH MOTILITY; STOMACH SECRETION; SYMPATHETIC TONE; TESTOSTERONE RELEASE; ANIMAL; BONE; CARTILAGE; CLINICAL TRIAL; METABOLISM;

ANIMALS; BONE AND BONES; CARTILAGE; CLINICAL TRIALS AS TOPIC; GHRELIN; HUMANS; INSULIN-LIKE GROWTH FACTOR I; RECEPTORS, GHRELIN;

EID: 77954783395     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (176)

1. Harada S, Rodan GA: Control of osteoblast function and regulation of bone mass. Nature, 2003; 423: 349-55
2. Van der Eerden BC, Karperien M, Wit JM: Systemic and local regulation of the growth plate. Endocr Rev, 2003; 24: 782-801
3. Bowers CY, Chang J, Momany FA, Folkers K: Effect of the enkephalins and enkephalin analogues on release of pituitary hormones in vitro. In: Molecular Endocrinology. editors MacIntyre G & Szelke H. Amsterdam: Elsevier, 1977; 287-92
4. Howard AD, Feighner SD, Cully DF et al: A receptor in pituitary and hypothalamus that functions in growth hormone release. Science, 1996; 273: 974-77
5. Murray DRCh, Kamm MA, Bloom SR, Emmanuel AV: Ghrelin for the Gastroenterologist: history and potential. Gastroenterology, 2003; 125: 1492-502
6. Korbonits M, Grossman AB: Growth hormone-releasing peptide and its analogues, novel stimuli to growth hormone release. Trends Endocrinol Metab, 1995; 6: 43-49
7. Smith RG: Development of Growth Hormone secretagogues. Endocr Rev, 2005; 6: 1-50
8. Kojima M, Hosoda H, Date Y et al: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 1999; 402: 656-60
9. Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB: Ghrelin-a hormone with multiple functions. Front Neuroendocrinol, 2004; 25: 27-68
10. Kojima M, Hosoda H, Matsuo H, Kangawa K: Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab, 2001; 3: 118-22
11. Hosoda H, Kojima M, Matsuo H, Kangawa K: Ghrelin and des-acyl ghrelin: Two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun, 2000; 279: 909-13
12. Van der Lely AJ, Tschop M, Heiman ML, Ghigo E: Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin. Endocr Rev, 2004; 25(3): 426-57
13. Pusztai P, Sarman B, Ruzicska E et al: Ghrelin: a new peptide regulating the neurohormonal system, energy homeostasis and glucose metabolism. Diabetes Metab Res Rev, 2008; 24(5): 343-52
14. Banks WA, Tschop M, Robinson SM, Heiman ML: Extent and direction of Ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther, 2002; 302: 822-27
15. Yang J, Brown MS, Liang G et al: Identification of the Acyltransferase that octanoylates Ghrelin, an appetite-stimulating peptide hormone. Cell, 2008; 132: 387-96
16. Gutierrez JA, Solenberg PJ, Perkins DR et al: Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci USA, 2008; 105(17): 6320-25
17. Date Y, Kojima M, Hosoda H et al: Ghrelin, a novel growth hormonereleasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology, 2000; 141: 4255-61
18. Wang HT, Lu QC, Wang Q et al: Role of the duodenum in regulation of plasma ghrelin levels and body mass index after subtotal gastrectomy. World J Gastroenterol, 2008; 14(15): 2425-29
19. Kojima M, Kangawa K: Ghrelin, an orexigenic signalling molecule from the gastrointestinal tract. Curr Opin Pharmacol, 2002; 2: 665-68
20. Korbonits M, Bustin SA, Kojima M et al: The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab, 2001; 86: 881-87
21. Moller N, Nygren J, Hansen TK et al: Splanchnic release of ghrelin in humans. J Clin Endocrinol Metab, 2003; 88: 850-52
22. Dixit VM, Schaffer EM, Taub DD: Ghrelin is expressed and secreted from human T lymphocytes and inhibits activation and leptin induced inflammatory cytokine expression via functional, lipid raft-associated growth hormone secretagogue receptors (GHS-R). Proceedings of the 85th Annual Meeting of the Endocrine Society, 2003; OR51-53
23. Hattori N, Saito T, Yagyu T et al: GH, GH receptor, GH secretagogue receptor, and ghrelin expression in human T cells, B cells, and neutrophils. J Clin Endocrinol Metab, 2001; 86: 4284-91
24. Volante M, Fulcheri E, Allia E et al: Ghrelin expression in fetal, infant, and adult human lung. J Histochem Cytochem, 2002; 50: 1013-21
25. Papotti M, Ghè C, Cassoni P et al: Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab, 2000; 85(10): 3803-7
26. Gualillo O, Caminos JE, Blanco M et al: Ghrelin, a novel placental-derived hormone. Endocrinology, 2001; 142: 788-94
27. Gaytan F, Barreiro ML, Chopin LK et al: Immunolocalization of ghrelin and its functional receptor, the type 1a growth hormone secretagogue receptor in the cyclic human ovary. J Clin Endocrinol Metab, 2003; 88: 879-87
28. Barreiro ML, Gaytán F, Caminos JE et al: Cellular location and hormonal regulation of ghrelin expression in rat testis. Biol Reprod, 2002; 67: 1768-76
29. Tena-Sempere M, Barreiro ML, González LC et al: Novel expression and functional role of ghrelin in rat testis. Endocrinology, 2002; 143: 717-25
30. Volante M, Allìa E, Gugliotta P et al: Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab, 2002; 87: 1300-8
31. Wierup N, Svensson H, Mulder H, Sundler F: The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas. Regul Pept, 2002; 107: 63-69
32. Van der Velde M, Delhanty P, van der Eerden B et al: Ghrelin and bone. Vitam & Horm, 2007; 77: 239-58
33. Fukushima N, Hanada R, Teranishi H et al: Ghrelin directly regulates bone formation. J Bone Miner Res, 2005; 20: 790-98
34. Maccarinelli G, Sibilia V, Torsello A et al: Ghrelin regulates proliferation and differentiation of osteoblastic cells. J Endocrinol, 2005; 184: 249-56
35. Miller MD: Review of orthopaedics. 5th ed. (eds.), Saunders: Elsevier, 2008; 18-21
36. Williams SE, Seigner DL: Metabolic bone disease in gastrointestinal illness. Gastroenterol Clin N Am, 2007; 36: 161-90
37. Bernstein CN, Leslie WD: The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol, 2003; 15: 857-64
38. Bassett JH, Williams GR: Critical role of the hypothalamic-pituitary-thyroid axis in bone. Bone, 2008; 43(3): 418-26
39. Naot D, Cornish J: The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism. Bone, 2008; 43(5): 813-18
40. Bouillon R, Carmeliet G, Verlinden L et al: Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev, 2008; 29(6): 726-76
41. Shapses SA, Riedt Cl: Bone, body weight and weight reduction: what are the concerns? J Nutrision, 2006; 136(6): 1453
42. Langlois JA, Mussolino ME, Visser M et al: Weight loss from maximum body weight among middle-aged and older white women and the risk of hip fracture: the NHANES I epidemiologic follow-up study. Osteoporos Int, 2001; 12: 763-68
43. Misra M: Long-term skeletal effects of eating disorders with onset in adolescence. Ann NY Acad Sci, 2008; 1135: 212-18
44. Legroux-Gérot I, Vignau J, D'Herbomez M et al: Evaluation of bone loss and its mechanisms in anorexia nervosa. Calcif Tissue Int, 2007; 81(3): 174-82
45. Lucas AR, Melton LJ III, Crowson CS, O'Fallon WM: Long-term fracture risk among women with anorexia nervosa: a population-based cohort study. Mayo Clin Proc, 1999; 74: 972-77
46. Hartman D, Crisp A, Rooney B et al: Bone density of women who have recovered from anorexia nervosa. Int J Eat Disord, 2000; 28: 107-12
47. Misra M, Klibanski A: Anorexia nervosa and osteoporosis. Rev Endocr Metab Disord, 2006; 7(1-2): 91-99
48. Hyams JS, Wyzga N, Kreutzer DL et al: Alterations in bone metabolism in children with inflammatory bowel disease: An in vitro study. J Pediatr Gastroenterol Nutr, 1997; 24: 289-95
49. Raisz LG: Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med, 1988; 318: 818-28
50. Kong YY, Feige U, Sarosi I et al: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature, 1999; 402: 304-9
51. Kanaan RA, Aldwaik M, Al-Hanbali OA: The role of connective tissue growth factor in skeletal growth and development. Med Sci Monit, 2006; 12(12): RA277-81
52. Kanaan RA, Kanaan LA: Transforming growth factor beta1, bone connection. Med Sci Monit, 2006; 12(8): RA164-69
53. Gilbert L, He X, Farmer P et al: Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology, 2000; 141: 3956-64
54. Azuma Y, Kaji K, Katogi R et al: Tumor necrosis factor alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem, 2000; 275: 4858-64
55. Bertolini DR, Nedwin GE, Bringman TS et al: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature, 1986; 319: 516-18
56. Kurokouchi K, Kambe F, Yasukawa K et al: TNF-alpha increases expression of IL-6 and ICAM-1 genes through activation of NF-kappa B in osteoblast- like ROS17 2.8 cells. J Bone Miner Res, 1998; 13: 1290-99
57. Nakashima T, Takayanagi H: Osteoclasts and the immune system. J Bone Miner Metab, 2009; 27(5): 519-29
58. Leibbrandt A, Penninger JM: RANKL/RANK as key factors for osteoclast development and bone loss in arthropathies. Adv Exp Med Biol, 2009; 649: 100-13
59. Aubin JE, Bonnelye E: Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int, 2000; 11: 905-13
60. Kong YY, Boyle WJ, Penninger JM: Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. Immunol Cell Biol, 1999; 77: 188-93
61. Lin CL, Moniz C, Chambers TJ, Chow JW: Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology, 1996; 111: 1263-71
62. Westerholm-Ormio M, Garioch J, Ketola I, Savilahti E: Inflammatory cytokines in small intestinal mucosa of patients with potential celiac disease. Clin Exp Immunol, 2002; 128: 94-101
63. Fornari MC, Pedreira S, Niveloni S et al: Pre- and post-treatment serum levels of cytokines IL-1beta, IL-6, and IL-1 receptor antagonist in celiac disease. Are they related to the associated osteopenia? Am J Gastroenterol, 1998; 93: 413-18
64. Dixit VD, Schaffer EM, Pyle RS et al: Ghrelin inhibits leptin- and activation- induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest, 2004; 114(1): 57-66
65. Prince M, Christensen E, Gluud C: Glucocorticosteroids for primary biliary cirrhosis. Cochrane Database Syst Rev, 2005; (2): CD003778
66. Shoback D, Marcus R, Bilke D: Metabolic bone disease. In: Greenspan FS, Gardner DG, editors. Basic and clinical endocrinology. 7th edition. New York: McGraw-Hill, 2004; 295-361
67. Cino M, Greenberg GR: Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol, 2002; 97(4): 915-21
68. Schoon EJ, Bollani S, Mills PR et al: Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol, 2005; 3: 113-21
69. Vestergaard P: Bone loss associated with gastrointestinal disease: Prevalence and pathogenesis. Eur J Gastroenterol Hepatol, 2003; 15: 851-56
70. Persson P, Gagnemo-Persson R, Chen D et al: Gastrectomy causes bone loss in the rat: Is lack of gastric acid responsible? Scand J Gastroenterol, 1993; 28: 301-6
71. Maier GW, Kreis ME, Zittel TT, Becker HD: Calcium regulation and bone mass loss after total gastrectomy in pigs. Ann Surg, 1997; 225(2): 181-92
72. American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal disease. Gastroenterology, 2003; 124(3): 791-94
73. Cui G L, Syversen U, Zhao CM et al: Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats. Scand J Gastroenterol, 2001; 36: 1011-15
74. Lehto-Axtelius D, Chen D, Surve VV, Hakanson R: Post-gastrectorny osteopenia in the rat. Scand J Gastroenterol, 2002; 37: 437-43
75. Popovic V, Miljic D, Pekic S et al: Low plasma ghrelin level in gastrectomized patients is accompanied by enhanced sensitivity to the ghrelin- induced growth hormone release. J Clin Endocrinol Metab, 2005; 90(4): 2187-91
76. Jeon TY, Lee S, Kim HH et al: Changes in plasma ghrelin concentration immediately after gastrectomy in patients with early gastric cancer. J Clin Endocrinol Metab, 2004; 89(11): 5392-96
77. Puzio I, Kapica M, Filip R et al: Fundectomy evokes elevated gastrin and lowered ghrelin serum levels accompanied by decrease in geometrical and mechanical properties of femora in rats. Bull Vet Inst Pulawy, 2005; 49: 69-73
78. Tatara MR, Krupski W, Sliwa E et al: Fundectomy-evoked osteopenia in pigs is mediated by the gastric-hypothalamic-pituitary axis. Exp Biol Med (Maywood), 2007; 232(11): 1449-57
79. Dornonville de la Cour C, Lindqvist A, Egecioglu E et al: Ghrelin treatment reverses the reduction in weight gain and body fat in gastrectomized mice. Gut, 2005; 54(7): 907-13
80. Sun YX, Ahmed S, Smith RG: Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol, 2003; 23: 7973-81
81. Giustina A, Mazziotti G, Canalis E: Growth hormone, Insulin-Like Growth Factors and the skeleton. Endocr Rev, 2008; 29: 535-59
82. Ueland T: GH/IGF-1 and bone resorption in vivo and in vitro. Europ J Endocrinol, 2005; 152: 327-32
83. Leung K, Rajkovic IA, Peters E et al: Insulin-like growth factor 1 and insulin down-regulate growth hormone (GH) receptors in rat osteoblasts: evidence for a peripheral feedback loop regulating GH action. Endocrinology, 1996; 137: 2694-702
84. Slootweg MC, Ohlsson C, Salles JP et al: Insulin-like growth factor binding proteins-2 and -3 stimulate growth hormone receptor binding and mitogenesis in rat osteosarcoma cells. Endocrinology, 1995; 136: 4210-17
85. Argetsinger LS, Campbell GS, Yang X, et al. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell, 1993; 74: 237-44
86. Lai CF, Chaudhary L, Fausto A et al: Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells. J Biol Chem, 2001; 276: 14443-50
87. Huang Z, Cheng SL, Slatopolsky E: Sustained activation of the extracellular signal-regulated kinase pathway is required for extracellular calcium stimulation of human osteoblast proliferation. J Biol Chem, 2001; 276: 21351-58
88. Xiao G, Gopalakrishnan R, Jiang D et al: Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. J Bone Miner Res, 2002; 17: 101-10
89. Ziros PG, Georgakopoulos T, Habeos I et al: Growth hormone attenuates the transcriptional activity of Runx2 by facilitating its physical association with Stat 3. J Bone Miner Res, 2004; 19: 1892-904
90. Barnard R, Ng KW, Martin TJ, Waters MJ: Growth hormone (GH) receptors in clonal osteoblast-like cells mediate a mitogenic response to GH. Endocrinology, 1991; 128: 1459-64
91. Kassem M, Blum W, Ristelli J et al: Growth hormone stimulates proliferation and differentiation of normal human osteoblast-like cells in vitro. Calcif Tissue Int, 1993; 52: 222-26
92. Digirolamo DJ, Mukherjee A, Fulzele K et al: Mode of growth hormone action in osteoblasts. J Biol Chem, 2007; 282: 31666-74
93. Canalis E, Economides AN, Gazzerro E: Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev, 2003; 24: 218-35
94. Lupu F, Terwilliger JD, Lee K et al: Roles of growth hormone and insulin- like growth factor 1 in mouse postnatal growth. Dev Biol, 2001; 229: 141-62
95. Canalis E, Centrella M, Burch W, McCarthy TL: Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest, 1989; 83: 60-65
96. Bikle DD, Sakata T, Leary C et al: Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res, 2002; 17: 1570-78
97. Ernst M, Rodan GA: Estradiol regulation of insulin-like growth factor- I expression in osteoblastic cells: evidence for transcriptional control. Mol Endocrinol, 1991; 5: 1081-89
98. Kassem M, Okazaki R, Harris SA et al: Estrogen effects on insulin-like growth factor gene expression in a human osteoblastic cell line with high levels of estrogen receptor. Calcif Tissue Int, 1998; 62: 60-66
99. Delany AM, Durant D, Canalis E: Glucocorticoid suppression of IGF-I transcription in osteoblasts. Mol Endocrinol, 2001; 15: 1781-89
100. Liu P, Baker J, Perkins AS et al: Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell, 1993; 75: 59-72
101. Wang J, Zhou J, Bondy CA: Igf1 promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy. FASEB J, 1999; 13: 1985-90
102. Doga M, Bonadonna S, Gola M et al: GH deficiency in the adult and bone. J Endocrinol Invest, 2005; 28(8 Suppl.): 18-23
103. Pun KK, Lau P, Wong FH et al: 25-Hydroxycholecalciferol and insulinlike growth factor I are determinants of serum concentration of osteocalcin in elderly subjects with and without spinal fractures. Bone, 1990; 11: 397-400
104. Gotherstrom G, Svensson J, Koranyi J et al: A prospective study of 5 years of GH replacement therapy in GH-deficient adults: Sustained effects on body composition, bone mass and metabolic indices. J Clin Endocrinol Metab, 2001; 86: 4657-65
105. Liu H, Bravata DM, Olkin I et al: Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med, 2007; 146(2): 104-15
106. Ebeling PR, Jones JD, O'Fallon WM et al: Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women. J Clin Endocrinol Metab, 1993; 77: 1384-87
107. Grinspoon SK, Baum HB, Peterson S, Klibanski A: Effects of rhIGF-1 administration on bone turnover during short-term fasting. J Clin Invest, 1995; 96: 900-6
108. Johansson AG, Lindh E, Blum WF et al: Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. J Clin Endocrinol Metab, 1996; 81: 44-48
109. Landin-Wilhelmsen K, Nilsson A, Bosaeus I, Bengtsson BA: Growth hormone increases bone mineral content in postmenopausal osteoporosis: A randomized placebo-controlled trial. J Bone Miner Res, 2003; 18: 393-405
110. Gillberg P, Mallmin H, Petren-Mallmin M et al: Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. J Clin Endocrinol Metab, 2002; 87: 4900-6
111. Cocchi D, Maccarinelli G, Sibilia V et al: GH-releasing peptides and bone. J Endocrinol Invest, 2005; 28: 11-14
112. Svensson J, Ohlsson C, Jansson JO et al: Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males. J Bone Miner Res, 1998; 13: 1158-66
113. Murphy MG, Bach MA, Plotkin D et al: Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. J Bone Miner Res, 1999; 14: 1182-88
114. Murphy MG, Weiss S, McClung M et al: Effect of alendronate and MK- 677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab, 2001; 86: 1116-25
115. Svensson J, Lall S, Dickson SL et al: The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol, 2000; 165: 569-77
116. Smith RG, Cheng K, Pong S-S: Mechanism of action of GHRP-6 and non-peptidyl growth hormone secretagogues. In: Bercu BB, Walker RF (eds.), Growth Hormone Secretagogues, Serono Symposia. New York: Springer-Verlag, 1996; 147-63
117. Sun Y, Wang P, Zheng H, Smith RG: Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA, 2004; 101: 4679-84
118. Sibilia V, Cocchi D, Pagani F et al: Hexarelin, a growth hormone - releasing peptide, counteracts bone loss in gonadectomized male rats. Growth Horm IGF Res, 1999; 9(4): 219-27
119. Sibilia V, Cocchi D, Villa I et al: Bone effects of hexarelin, a GH-releasing peptide, in female rats: influence of estrogen milieu. Eur J Endocrinol, 2002; 146(6): 855-62
120. Leontiou CA, Franchi G, Korbonits M: Ghrelin in neuroendocrine organs and tumours. Pituitary, 2007; 10(3): 213-25
121. de Herder WW: Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab, 2007; 21(1): 33-41
122. Higgins SC, Gueorguiew M, Korbonits M: Ghrelin, the peripheral hunger hormone. Ann Med, 2007; 39: 116-36
123. Belloni AS, Macchi C, Rebuffat P et al: Effect of ghrelin on the apoptotic deletion rate of different types of cells cultured in vitro. Int J Mol Med, 2004; 14: 165-67
124. Kim SW, Her SJ, Park SJ et al: Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. Bone, 2005; 37: 359-69
125. Delhanty PJD, van der Eerden BCJ, van der Velde M, et al: Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a. J Endocrinol, 2006; 188: 37-47 RA
126. Li WG, Gavrila D, Liu X et al: Ghrelin inhibits pro-inflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation, 2004; 109: 2221-26
127. Waseem T, Duxbury M, Ito H et al: Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. Surgery, 2008; 143: 334-42
128. Xia Q, Pang W, Pan H et al: Effects of ghrelin on the proliferation and secretion of splenic T lymphocytes in mice. Regulat Pept, 2004; 122: 173-78
129. Gonzalez-Rey E, Chorny A, Delgado M: Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology, 2006; 130: 1707-20
130. Granata R, Settanni F, Biancone L et al: Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human islets: involvement of 30,50-cyclic adenosine monophosphate/ protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl inositol 3-kinase/Akt signaling. Endocrinology, 2007; 148: 512-29
131. Otero M, Noqueiras R, Lago F et al: Chronic inflammation modulates ghrelin levels in human and rats. Rheumatology, 2004; 43: 306-10
132. Karmiris K, Koutroubanis IE, Kouroumalis EA: Leptin, adiponectin, resistin and ghrelin- implications for inflammatory bowel desease. Mol Nutr Food Res, 2008; 52: 855-66
133. Kerem M, Bedirli A, Pasaoglu H et al: Role of ghrelin and leptin in predicting the severity of acute pancreatitis. Digest Dis Sci, 2007; 52: 950-55
134. Wang DH, Hu YS, Du JJ et al: Ghrelin stimulates proliferation of human osteoblastic TE85 cells via NO/cGMP signaling pathway. Endocrine, 2009; 35(1): 112-17
135. Caminos JE, Gualillo O, Lago F et al: The endogenous growth hormone secretagogue (ghrelin) is synthesized and secreted by chondrocytes. Endocrinology, 2004; 146(3): 1285-92
136. Jikko A, Murakami H, Yan W et al: Effects of cyclic adenosine 3,5-monophosphate on chondrocyte terminal differentiation and cartilagematrix calcification. Endocrinology, 1996; 137: 122-28
137. Miwa M, Saura R, Hirata S et al: Induction of apoptosis in bovine articular chondrocyte by prostaglandin E(2) through cAMP-dependent pathway. Osteoarthritis Cartilage, 2000; 8: 17-24
138. Ghigo E, Arvat E, Giordano R et al: Biologic activities of growth hormone secretagogues in humans. Endocrine, 2001; 14: 87-93
139. Lebrethon MC, Aganina A, Fournier M et al: Effects of in vivo and in vitro administration of ghrelin, leptin and neuropeptide mediators on pulsatile gonadotrophin-releasing hormone secretion from male rat hypothalamus before and after puberty. J Neuroendocrinol, 2007; 19(3): 181-88
140. Nikolopoulos D, Theocharis S, Kouraklis G: Ghrelin's role on gastrointestinal tract cancer. Surg Oncol, 2010; 19(1): e2-10
141. Arnaldi G, Mancini T, Kola B et al: Cyclical Cushing's syndrome in a patient with a bronchial neuroendocrine tumor (typical carcinoid) expressing ghrelin and growth hormone secretagogue receptors. J Clin Endocrinol Metab, 2003; 88(12): 5834-40
142. Thomas GB, Bennett PA, Carmignac DF, Robinson IC: Glucocorticoid regulation of growth hormone (GH) secretagogue-induced growth responses and GH secretagogue receptor expression in the rat. Growth Horm IGF Res, 2000; 10(1): 45-52
143. Korbonits M, Kaltsas G, Perry LA et al: The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab, 1999; 84(7): 2489-95
144. Cowley MA, Smith RG, Diano S et al: The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron, 2003; 37(4): 649-61
145. Giordano R, Picu A, Broglio F et al: Ghrelin, hypothalamus-pituitary-adrenal (HPA) axis and Cushing's syndrome. Pituitary, 2004; 7(4): 243-48
146. Kim K, Arai K, Sanno N et al: Ghrelin and growth hormone (GH) secretagogue receptor (GHSR) mRNA expression in human pituitary adenomas. Clin Endocrinol (Oxf), 2001; 54: 759-68
147. Delhanty PJ, van Koetsveld PM, Gauna C et al: Ghrelin and its unacylated isoform stimulate the growth of adrenocortical tumor cells via an antiapoptotic pathway. Am J Physiol Endocrinol Metab, 2007; 293(1): E302-9
148. de Keyzer Y, Lenne F, Bertagna X: Widespread transcription of the growth hormone-releasing peptide receptor gene in neuroendocrine human tumors. Eur J Endocrinol, 1997; 137: 715-18
149. Broglio F, Arvat E, Benso A et al: Ghrelin: Much More than a Natural Growth Hormone Secretagogue. IMAJ, 2002; 4: 607-13
150. Gualillo O, Caminos JE, Kojima M et al: Gender and gonadal influences on ghrelin mRNA levels in rat stomach. Eur J Endocrinol, 2001; 144: 687-90
151. Otto B, Tschöp M, Heldwein W et al: Endogenous and exogenous glucocorticoids decrease plasma ghrelin in humans. Eur J Endocrinol, 2004; 151(1): 113-17
152. Prince M, Christensen E, Gluud C: Glucocorticosteroids for primary biliary cirrhosis. Cochrane Database Syst Rev, 2005; (2): CD003778
153. Li WG, Gavrila D, Liu X et al: Ghrelin inhibits pro-inflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation, 2004; 109: 2221-26
154. Zhao D, Zhan Y, Zeng H et al: Ghrelin stimulates interleukin-8 gene expression through protein kinase C-mediated NF-kappaB pathway in human colonic epithelial cells. J Cell Biochem, 2006; 97: 1317-27
155. Antoniazzi F, Zamboni G, Bertoldo F et al: Bone development during GH and GnRH analog treatment. Europ J Endocrinol, 2004; 151: S47-54
156. Deng F, Ling J, Ma J, Liu C, Zhang W: Stimulation of intramembranous bone repair in rats by ghrelin. Exp Physiol, 2008; 93(7): 872-79
157. Conover CA, Johnstone EW, Turner RT et al: Subcutaneous administration of insulin-like growth factor (IGF)-II/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis. Growth Horm IGF Res, 2002; 12(3): 178-83
158. Palermo C, Manduca P, Gazzerro E et al: Potentiating role of IGFBP-2 on IGF-II-stimulated alkaline phosphatase activity in differentiating osteoblasts. Am J Physiol Endocrinol Metab, 2004; 286(4): E648-57
159. Vincent C, Findlay DM, Welldon KJ et al: Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res, 2009; 24(8): 1434-49
160. Karmiris K, Koutroubakis IE, Xidakis C et al: Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm. Bowel Dis, 2006; 12: 100-5
161. Toussirot E, Streit G, Nguyen NU et al: Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. Metabolism, 2007; 56(10): 1383-89
162. Koca SS, Ozgen M, Aydin S et al: Ghrelin and obestatin levels in rheumatoid arthritis. Inflammation, 2008; 31(5): 329-35
163. Maruna P, Górlich R, Frasko R, Rosicka M: Ghrelin and leptin elevation in postoperative intra-abdominal sepsis. Eur Surg Res, 2005; 37: 354-59
164. Chorny A, Anderson P, Gonzalez-Rey E, Delgado M: Ghrelin protects against experimental sepsis by inhibiting high-modility group box-1 release and by kinning bacteria. J Immunology, 2008; 180: 8369-77
165. Kerem M, Bedirli A, Pasaoglu H et al: Role of ghrelin and leptin in predicting the severity of acute pancreatitis. Digest Dis Sci, 2007; 52: 950-55
166. Granado M, Priego T, Martin AI et al: Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab, 2005; 288: E486-92
167. Zhao D, Zhan Y, Zeng H et al: Ghrelin stimulates interleukin-8 gene expression through protein kinase C-mediated NF-kappaB pathway in human colonic epithelial cells. J Cell Biochem, 2006; 97: 1317-27
168. Otero M, Noqueiras R, Lago F et al: Chronic inflammation modulates ghrelin levels in human and rats. Rheumatology, 2004; 43: 306-10
169. Hattori N: Expression, regulation and biological actions of growth hormone (GH) and ghrelin in the immune system. Growth Horm IGF Res, 2009; 19: 187-97
170. Vila G, Maier C, Riedl M et al: Bacterial endotoxin induces biphasic changes in plasma ghrelin in healthy humans. J Clin Endocrinol Metab, 2007; 92: 3930-34
171. Pérez-Castrillón JL, Justo I, Sanz A et al: Ghrelin and bone mass in postmenopausal hypertensive women. Ann Nutr Metab, 2007; 51(3): 223-27
172. Misra M, Miller KK, Kuo K et al: Secretory dynamics of ghrelin in adolescent girls with anorexia nervosa and healthy adolescents. Am J Physiol Endocrinol Metab, 2005; 289: E347-56
173. Misra M, Miller KK, Stewart V et al: Ghrelin and bone metabolism in adolescents girls with anorexia nervosa and healthy adolescents. J Clin Endocrin Metabol, 2005; 90(9): 5082-87
174. Misra M, Klibanski A: Anorexia nervosa and osteoporosis. Rev Endocr Metab Disord, 2006; 7: 91-99
175. Vulliemoz NR, Xiao E, Xia-Zhang L et al: Decrease in luteinizing hormone pulse frequency during a five-hour peripheral ghrelin infusion in the ovariectomized rhesus monkey. J Clin Endocrinol Metab, 2004; 89: 5718-23
176. Camurdan MO, Bideci A, Demirel F, Cinaz P: Serum ghrelin, IGF-1 and IGFBP-3 levels in children with normal variant short stature. Endocr J, 2006; 53(4): 479-84